RNA blood levels of osteopontin splice variants are cancer markers

SpringerPlus

Volumn 2, Issue 1, 2013, Pages 1-8

  Hartung, Franz ^a   Weber, Georg F ^a  

^a UNIVERSITY OF CINCINNATI ACADEMIC HEALTH CENTER   (United States)

Author keywords

Biomarker; Blood analysis; Breast cancer; Cancer progression; Lung cancer

Indexed keywords

EID: 84876585563     PISSN: None     EISSN: 21931801     Source Type: Journal    
DOI: 10.1186/2193-1801-2-110     Document Type: Article

References (16)

1. Beitsch PD, Clifford E (2000) Detection of carcinoma cells in the blood of breast cancer patients. Am J Surgery 180:446-449
2. Chang YS, Kim HJ, Chang J, Ahn CM, Kim SK, Kim SK (2007) Elevated circulating level of osteopontin is associated with advanced disease state of non-small cell lung cancer. Lung Cancer 57:373-380
3. Craig AM, Nemir M, Mukherjee BB, Chambers AF, Denhardt DT (1988) Identification of the major phosphoprotein secreted by many rodent cell lines as 2ar/osteopontin: enhanced expression in H-ras-transformed 3 T3 cells. Biochem Biophys Res Commun 157:166-173
4. Fedarko NS, Jain A, Karadag A, Van Eman MR, Fisher LW (2001) Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer. Clin Cancer Res 7:4060-4066
5. Hardingham JE, Hewett PJ, Sage RE, Finch JL, Nuttall JD, Kotasek D, Dobrovic A (2000) Molecular detection of blood-borne epithelial cells in colorectal cancer patients and in patients with benign bowel disease. Int J Cancer 89:8-13
6. He B, Mirza M, Weber GF (2006) An osteopontin splice variant induces anchorage independence in human breast cancer. Oncogene 25:2192-2202
7. Mack PC, Redman MW, Chansky K, Williamson SK, Farneth NC, Lara PN Jr, Franklin WA, Le QT, Crowley JJ, Gandara DR (2008) Lower osteopontin plasma levels are associated with superior outcomes in advanced non-small-cell lung cancer patients receiving platinum-based chemotherapy: SWOG Study S0003. J Clin Oncol 26:4771-4776
8. Mirza M, Shaughnessy E, Hurley JK, Vanpatten KA, Pestano GA, He B, Weber GF (2008) Osteopontin-c is a selective marker for breast cancer. Int J Cancer 122:889-897
9. Mountzios G, Dimopoulos MA, Bamias A, Papadopoulos G, Kastritis E, Syrigos K, Pavlakis G, Terpos E (2007) Abnormal bone remodeling process is due to an imbalance in the receptor activator of nuclear factor-kappaB ligand (RANKL)/ osteoprotegerin (OPG) axis in patients with solid tumors metastatic to the skeleton. Acta Oncol 46:221-229
10. Pfaffl MW (2001) A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29:e45
11. Senger DR, Perruzzi CA, Papadopoulos A (1989) Elevated expression of secreted phosphoprotein I (osteopontin, 2ar) as a consequence of neoplastic transformation. Anticancer Res 9:1291-1299
12. Sullivan J, Blair L, Alnajar A, Aziz T, Ng CY, Chipitsyna G, Gong Q, Witkiewicz W, Weber GF, Yeo CJ, Arafat HA (2009) Expression of a pro-metastatic splice variant of Osteopontin, OPNc, in human pancreatic ductal adenocarcinoma. Surgery 146:232-240
13. Tilli TM, Franco VF, Robbs BK, Wanderley JL, Silva F, Duarte de Mello K, Viola JPB, Weber GF, Gimba ERP (2011) Osteopontin-c splicing isoform contributes to ovarian cancer progression. Mol Cancer Res 9:280-293
14. Weber GF, Lett S, Haubein N (2010) Osteopontin is a marker for cancer aggressiveness and patient survival. Brit J Cancer 103:861-869
15. Weber GF, Lett GS, Haubein NC (2011) Meta-analysis of Osteopontin as a clinical cancer marker. Oncol Rep 25:433-441
16. Weber GF (2011) The cancer biomarker osteopontin: combination with other markers. Cancer Genomics Proteomics 8:263-288